Drugs / KLH conjugates with GD2L and GD3L
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT00597272 | Dec 2007 → Nov 2012 | melanoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KLH conjugates with GD2L and GD3L | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00597272 ↗ |
| Modality | Vaccine | “We will vaccinate you with the modified forms of GD2 called GD2 lactone and GD3 called GD3 lactone (GD3L), all attached to the antibody booster KLH” NCT00597272 ↗ |